NSAID-induced gastrointestinal toxicity.

Bulletin on the rheumatic diseases Pub Date : 1995-05-01
L S Simon, T Goodman
{"title":"NSAID-induced gastrointestinal toxicity.","authors":"L S Simon,&nbsp;T Goodman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Recommendations that can be made to decrease the incidence of untoward NSAID-induced GI events include identification of the high-risk patient (Table 3). If it is important to treat these high-risk patients with NSAIDs, either the lowest possible dose of the NSAID, an alternative non-NSAID analgesic, or the nonacetylated salicylates should be used. If that is impossible and a nonsalicylate NSAID is required in the high-risk patient, one should treat concomitantly with tolerable doses of misoprostol and prescribe that the NSAID be taken with food. If the patient is intolerant of misoprostol, H2 antagonists or omeprazole should be considered to decrease the risk of developing an NSAID-induced duodenal ulcer. If patients are not in the defined high-risk groups, given the present costs of H2 antagonists, omeprazole, and misoprostol, there seems to be little justification in treating the patient prophylactically. However, if the patient develops progressive iron-deficiency anemia or occult fecal blood loss not due to an obvious malignancy, endoscopy can be recommended to determine the cause. If there is evidence of a significant NSAID-induced gastric or duodenal ulcer, the NSAID should be stopped and the ulcer treated. If that is impossible, the NSAID dosage should be as low as possible, and the ulcer treated. If an ulcer is found, either a biopsy for H. pylori or a serum assay for the organism should be obtained. Once the ulcer is healed through appropriate therapy, and if NSAIDs are still to be used, prophylaxis with misoprostol should be considered.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":75657,"journal":{"name":"Bulletin on the rheumatic diseases","volume":"44 3","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"1995-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin on the rheumatic diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Recommendations that can be made to decrease the incidence of untoward NSAID-induced GI events include identification of the high-risk patient (Table 3). If it is important to treat these high-risk patients with NSAIDs, either the lowest possible dose of the NSAID, an alternative non-NSAID analgesic, or the nonacetylated salicylates should be used. If that is impossible and a nonsalicylate NSAID is required in the high-risk patient, one should treat concomitantly with tolerable doses of misoprostol and prescribe that the NSAID be taken with food. If the patient is intolerant of misoprostol, H2 antagonists or omeprazole should be considered to decrease the risk of developing an NSAID-induced duodenal ulcer. If patients are not in the defined high-risk groups, given the present costs of H2 antagonists, omeprazole, and misoprostol, there seems to be little justification in treating the patient prophylactically. However, if the patient develops progressive iron-deficiency anemia or occult fecal blood loss not due to an obvious malignancy, endoscopy can be recommended to determine the cause. If there is evidence of a significant NSAID-induced gastric or duodenal ulcer, the NSAID should be stopped and the ulcer treated. If that is impossible, the NSAID dosage should be as low as possible, and the ulcer treated. If an ulcer is found, either a biopsy for H. pylori or a serum assay for the organism should be obtained. Once the ulcer is healed through appropriate therapy, and if NSAIDs are still to be used, prophylaxis with misoprostol should be considered.(ABSTRACT TRUNCATED AT 250 WORDS)

非甾体抗炎药引起的胃肠道毒性。
减少非甾体抗炎药诱导的不良胃肠道事件发生率的建议包括识别高危患者(表3)。如果用非甾体抗炎药治疗这些高危患者很重要,则应使用尽可能低剂量的非甾体抗炎药、替代的非甾体抗炎药镇痛药或非乙酰化水杨酸盐。如果这是不可能的,而高风险患者需要非水杨酸类非甾体抗炎药,则应同时使用可耐受剂量的米索前列醇,并规定非甾体抗炎药与食物一起服用。如果患者对米索前列醇不耐受,应考虑H2拮抗剂或奥美拉唑,以降低发生非甾体抗炎药诱导的十二指肠溃疡的风险。如果患者不在定义的高危人群中,考虑到目前H2拮抗剂、奥美拉唑和米索前列醇的成本,似乎没有理由对患者进行预防性治疗。然而,如果患者发展为进行性缺铁性贫血或隐蔽性粪出血,而不是由于明显的恶性肿瘤,则可建议内镜检查以确定病因。如果有明显的非甾体抗炎药引起的胃或十二指肠溃疡的证据,应停止使用非甾体抗炎药并治疗溃疡。如果这是不可能的,非甾体抗炎药的剂量应该尽可能低,并治疗溃疡。如果发现溃疡,应进行幽门螺杆菌活组织检查或该有机体的血清化验。一旦溃疡通过适当的治疗愈合,如果非甾体抗炎药仍在使用,应考虑使用米索前列醇进行预防。(摘要删节250字)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信